Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint ...Middle East

BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi,...

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint )

Also on site :

Which Tiny “Purse” Dog Breed Are You, Based on Your Zodiac Sign
Mexican cartel turf war forces evacuation of exotic animals
Australia-India Financing Venture Southern Sitara Bows at Cannes Market With Cross-Cultural Slate (EXCLUSIVE)

Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint ...Middle East

A dozen black holes may be 'wandering' through our galaxy — and they're the rarest type in the universe

Jennifer Aniston’s accused stalker found mentally incompetent for trial

Correctional officer at Vacaville prison injured in alleged attack by inmate

The Memorial Day travel rush is off to an early start

In Mexico, Songs for Women who Kill Their Abusers

Hampton Roads football legend Tommy Reamon dies at 73

Tinder CEO to step down in July

Endries International Announces Leadership Transition

This Rugged and Portable Sony Speaker Is $50 Off

This Just In: A Pause to Remember

Man shot several times after dispute in Oakland’s San Antonio neighborhood

NASA Astronaut to Answer Questions from Students in Washington State

Cannes: Hasan Hadi’s ‘The President’s Cake’ Wins Directors’ Fortnight Audience Award

Palestine Legal Attorney Dylan Saba Slammed for Calling Jewish Deaths an Occupational Hazard

Dave Shapiro, Music Agent & Sound Talent Group Owner, Killed in San Diego Plane Crash at 42